Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4926874 | 0.83 | — | — | |
| SCHEMBL4923630 | 0.83 | — | — | |
| SCHEMBL448650 | 0.69 | — | — | |
| SCHEMBL350964 | 0.69 | — | — | |
| SCHEMBL2267757 | 0.67 | — | — | |
| SCHEMBL4853131 | 0.67 | ABL1 (0.36) | CYP1A1CYP1B1 | |
| SCHEMBL57641 | 0.67 | ALDH1A1 (0.41) | CYP1A1CYP1B1 | |
| SCHEMBL4479122 | 0.67 | HTT (0.41) | — | |
| SCHEMBL4396043 | 0.65 | ACHE (0.48) | — | |
| SCHEMBL3447464 | 0.65 | AGXT (0.41) | CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| CN-1169792-C | Substituted vinylpyridine derivatives and medicaments containing them | ������ҩ��ʽ���� | 2004-10-06 | — | — | CN | claimed |
| CN-114213353-B | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| EP-2430004-B1 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| EP-2429523-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430004-A2 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131191-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| CN-1169792-C | Substituted vinylpyridine derivatives and medicaments containing them | ������ҩ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| EP-0882714-B1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS PHARMACEUTICAL CO (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-5935977-A | PHOSPHODIESTERASE IV INHIBITORS, TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORS; TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | SS PHARMACEUTICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| CN-1206407-A | Substituted vinylpyridine derivatives and medicaments containing them | SS PHARMACEUTICAL CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| EP-0882714-A1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS Pharmaceutical Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CYP1A1 720/4885CYP1B1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.